がん免疫療法創薬アウトソーシング市場- 世界の産業規模、シェア、動向、機会、予測、薬剤タイプ別、サービスタイプ別、がんタイプ別、地域別セグメント、競合、2020年～2030年

がん免疫療法創薬アウトソーシングの世界市場規模は2024年に12億9,000万米ドルで、予測期間中のCAGRは8.80%で2030年には21億4,000万米ドルに達すると予測されています。

がん免疫療法創薬アウトソーシングは、製薬・バイオテクノロジー業界に特化したサービスモデルです。がん免疫療法の創薬・開発プロセスの様々な側面を、CRO（Contract Research Organization：研究開発業務受託機関）やCDMO（Contract Development and Manufacturing Organization：開発製造業務受託機関）として知られる外部のサービスプロバイダーにアウトソーシングするものです。このアウトソーシングモデルは、製薬企業が外部の専門知識、インフラ、リソースを活用することで、革新的ながん免疫療法の開発を加速させることを目的としています。がん免疫療法の創薬プロセスには通常、ターゲット同定、前臨床研究、臨床試験管理、薬事承認などいくつかの段階が含まれます。アウトソーシングはこれらの段階の様々な側面をカバーすることができます。外部委託先とリスクを共有することは、製薬業界では一般的な戦略です。外部の専門家と提携することで、企業は科学的リスクと財務的リスクを軽減することができます。免疫チェックポイント阻害剤、CAR-T細胞療法、モノクローナル抗体などの免疫療法アプローチの急速な開発と成功は、この分野への大きな関心と投資を促しました。個別化医療へのシフトにより、個々の患者に特異的なバイオマーカーや遺伝的標的の特定に焦点が当てられています。そのため、バイオマーカー探索や医薬品開発のアウトソーシングサービスが必要とされています。患者は免疫療法が有効ながん治療の選択肢であることを認識するようになり、しばしばこうした治療を求めるようになっています。このような患者の需要の高まりが、製薬会社を免疫療法創薬への投資に駆り立てています。研究によりがんの遺伝的・分子的メカニズムに関する新たな知見が発見されるにつれ、希少がんを含むより幅広いがん種に対する免疫療法の開発に焦点が当てられるようになっています。ターゲット同定、前臨床研究、臨床試験管理など、創薬の特定の側面をアウトソーシングすることで、製薬会社は研究開発コストを削減し、リソースをより効率的に配分することができます。

市場促進要因

患者の需要と意識の高まり

市場の課題

品質管理と標準化

主な市場動向

チェックポイント阻害薬の調査増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のがん免疫療法創薬アウトソーシング市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤タイプ別（モノクローナル抗体、免疫調節薬、がんワクチン、腫瘍溶解性ウイルス療法など）
  • サービスタイプ別（ターゲットの特定と検証、リードスクリーニングと特性評価、細胞ベースのアッセイ）
  • がんタイプ別（肺がん、乳がん、大腸がん、黒色腫、前立腺がん、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域のがん免疫療法創薬アウトソーシング市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州のがん免疫療法創薬アウトソーシング市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米のがん免疫療法創薬アウトソーシング市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米のがん免疫療法創薬アウトソーシング市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのがん免疫療法創薬アウトソーシング市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のがん免疫療法創薬アウトソーシング市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Covance, Inc.
• Horizon Discovery Group PLC
• Crown Bioscience, Inc.
• Promega Corporation
• HD Biosciences Co., Ltd.
• BPS Bioscience, Inc.
• Genscript Biotech Corporation
• DiscoverX Corporation
• Celentyx Ltd.
• ImmunXperts SA

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Cancer Immunotherapy Drug Discovery Outsourcing Market was valued at USD 1.29 billion in 2024 and is expected to reach USD 2.14 billion by 2030 with a CAGR of 8.80% during the forecast period. Cancer Immunotherapy Drug Discovery Outsourcing is a specialized service model within the pharmaceutical and biotechnology industry. It involves the outsourcing of various aspects of the drug discovery and development process for cancer immunotherapies to external service providers, often known as Contract Research Organizations (CROs) or Contract Development and Manufacturing Organizations (CDMOs). This outsourcing model is designed to accelerate the development of innovative cancer immunotherapies while allowing pharmaceutical companies to leverage external expertise, infrastructure, and resources. The drug discovery process for cancer immunotherapies typically involves several stages, including target identification, preclinical research, clinical trial management, and regulatory approval. Outsourcing can cover various aspects of these stages. Sharing risks with outsourcing partners is a common strategy in the pharmaceutical industry. By partnering with external experts, companies can mitigate scientific and financial risks. The rapid development and success of immunotherapy approaches, such as immune checkpoint inhibitors, CAR-T cell therapies, and monoclonal antibodies, have driven significant interest and investment in the field. The shift toward personalized medicine has led to a focus on identifying specific biomarkers and genetic targets for individual patients. This necessitates outsourcing services for biomarker discovery and drug development. Patients are becoming more aware of immunotherapy as a viable cancer treatment option, and they often seek out these therapies. This increased patient demand drives pharmaceutical companies to invest in immunotherapy drug discovery. As research uncovers new insights into the genetic and molecular mechanisms of cancer, the focus on developing immunotherapies for a broader range of cancer types, including rare cancers, has increased. Outsourcing certain aspects of drug discovery, such as target identification, preclinical research, and clinical trial management, helps pharmaceutical companies reduce research and development costs and allocate resources more efficiently.

Key Market Drivers

Increasing Patient Demand and Awareness

Patients today have greater access to information about cancer treatment options, including immunotherapy, through the internet, social media, and patient advocacy groups. This increased awareness leads patients to seek out the latest and most promising therapies. Many patients with cancer are seeking innovative and more effective treatments, especially when traditional therapies have not yielded satisfactory results or are associated with significant side effects. Immunotherapies represent a promising and less toxic approach. Awareness about the concept of personalized medicine has grown. Patients are increasingly aware that cancer immunotherapies can be tailored to their specific genetic and molecular profiles, making them more effective and less likely to cause adverse effects. Patients are more willing to participate in clinical trials, as they recognize the potential benefits of receiving cutting-edge treatments. Clinical trials often rely on outsourcing services for various aspects, including patient recruitment and data management. Patient advocacy groups and organizations dedicated to specific types of cancer actively promote awareness about the latest treatments, including immunotherapies. They often collaborate with researchers and pharmaceutical companies, indirectly contributing to the growth of outsourcing services. As patients become more informed, they engage in discussions with their healthcare providers about treatment options, including immunotherapy. This dialogue drives interest in these therapies and encourages healthcare professionals to explore outsourcing for the latest treatments.

Key Market Challenges

Quality Control and Standardization

The drug discovery process for cancer immunotherapies is complex and continually evolving. Ensuring consistent quality and standards across different stages of this process, from target identification to clinical trials, is a significant challenge. Outsourcing projects often involve multiple sites, including research organizations, pharmaceutical companies, and contract research organizations (CROs). Coordinating and maintaining quality standards across these different entities can be challenging. Immunotherapy research and development employ a wide range of technologies and techniques, from genomics to cell-based assays. Standardizing procedures and ensuring quality across these diverse methods is essential. Quality control extends to data management and integration. Diverse data sources, such as genomics data, clinical trial data, and patient records, need to be standardized and integrated for comprehensive analysis.

Key Market Trends

Increasing Research in Checkpoint Inhibitors

Checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, have demonstrated substantial clinical success in the treatment of various cancers, including melanoma, lung cancer, and more. This success has driven increased research and development in this area. Research is ongoing to explore the use of checkpoint inhibitors for a broader range of cancer types and stages. This expansion of indications requires extensive outsourcing services for clinical trial management and patient recruitment. Researchers are investigating combinations of checkpoint inhibitors with other immunotherapies, chemotherapy, targeted therapies, and radiation therapy. This approach requires extensive research and outsourcing support. Identifying predictive and prognostic biomarkers to guide the use of checkpoint inhibitors is a key focus of research. Outsourcing services play a critical role in biomarker discovery. The trend toward personalized medicine in cancer treatment emphasizes the need to identify which patients are most likely to benefit from checkpoint inhibitors. Outsourcing services contribute to this patient-centric approach.

Key Market Players

• Covance, Inc.
• Horizon Discovery Group PLC
• Crown Bioscience, Inc.
• Promega Corporation
• HD Biosciences Co., Ltd.
• BPS Bioscience, Inc.
• Genscript Biotech Corporation
• DiscoverX Corporation
• Celentyx Ltd.
• ImmunXperts SA

Report Scope:

In this report, the Global Cancer Immunotherapy Drug Discovery Outsourcing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Immunotherapy Drug Discovery Outsourcing Market, By Service Type:

• Target Identification and Validation
• Lead Screening and Characterization
• Cell-based Assays

Cancer Immunotherapy Drug Discovery Outsourcing Market, By Drug Type:

• Monoclonal Antibodies
• Immunomodulators
• Cancer Vaccines and Oncolytic Viral Therapy
• others

Cancer Immunotherapy Drug Discovery Outsourcing Market, By Cancer Type:

• Lung
• Breast
• Colorectal
• Melanoma
• Prostate
• Others

Cancer Immunotherapy Drug Discovery Outsourcing Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Immunotherapy Drug Discovery Outsourcing Market.

Available Customizations:

Global Cancer Immunotherapy Drug Discovery Outsourcing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Monoclonal Antibodies, Immunomodulators, Cancer Vaccines and Oncolytic Viral Therapy, others)
  • 5.2.2. By Service Type (Target Identification and Validation, Lead Screening and Characterization, Cell-based Assays)
  • 5.2.3. By Cancer Type (Lung, Breast, Colorectal, Melanoma, Prostate, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Service Type
  • 6.2.3. By Cancer Type
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Service Type
      • 6.3.1.2.3. By Cancer Type
  • 6.3.2. India Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Service Type
      • 6.3.2.2.3. By Cancer Type
  • 6.3.3. Australia Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Service Type
      • 6.3.3.2.3. By Cancer Type
  • 6.3.4. Japan Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug Type
      • 6.3.4.2.2. By Service Type
      • 6.3.4.2.3. By Cancer Type
  • 6.3.5. South Korea Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug Type
      • 6.3.5.2.2. By Service Type
      • 6.3.5.2.3. By Cancer Type

7. Europe Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Service Type
  • 7.2.3. By Cancer Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Service Type
      • 7.3.1.2.3. By Cancer Type
  • 7.3.2. Germany Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Service Type
      • 7.3.2.2.3. By Cancer Type
  • 7.3.3. Spain Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Service Type
      • 7.3.3.2.3. By Cancer Type
  • 7.3.4. Italy Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Service Type
      • 7.3.4.2.3. By Cancer Type
  • 7.3.5. United Kingdom Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Service Type
      • 7.3.5.2.3. By Cancer Type

8. North America Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Service Type
  • 8.2.3. By Cancer Type
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Service Type
      • 8.3.1.2.3. By Cancer Type
  • 8.3.2. Mexico Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Service Type
      • 8.3.2.2.3. By Cancer Type
  • 8.3.3. Canada Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Service Type
      • 8.3.3.2.3. By Cancer Type

9. South America Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Service Type
  • 9.2.3. By Cancer Type
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Service Type
      • 9.3.1.2.3. By Cancer Type
  • 9.3.2. Argentina Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Service Type
      • 9.3.2.2.3. By Cancer Type
  • 9.3.3. Colombia Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Service Type
      • 9.3.3.2.3. By Cancer Type

10. Middle East and Africa Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Service Type
  • 10.2.3. By Cancer Type
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Service Type
      • 10.3.1.2.3. By Cancer Type
  • 10.3.2. Saudi Arabia Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Service Type
      • 10.3.2.2.3. By Cancer Type
  • 10.3.3. UAE Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Service Type
      • 10.3.3.2.3. By Cancer Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Cancer Immunotherapy Drug Discovery Outsourcing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Covance, Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Horizon Discovery Group PLC
• 16.3. Crown Bioscience, Inc.
• 16.4. Promega Corporation
• 16.5. HD Biosciences Co., Ltd.
• 16.6. BPS Bioscience, Inc.
• 16.7. Genscript Biotech Corporation
• 16.8. DiscoverX Corporation
• 16.9. Celentyx Ltd.
• 16.10. ImmunXperts SA

17. Strategic Recommendations

18. About Us & Disclaimer